RTI Surgical Rebrands as Evergen, a Regenerative Medicine CDMO

RTI Surgical, a contract design and manufacturing (CDMO) company specializing in tissue engineering and regenerative medicine, has revealed a new corporate identity as Evergen.

The company said this move signals a strategic evolution into a premier CDMO providing biosolutions in regenerative medicine.

This rebranding comes after the company acquired Cook Biotech and Collagen Solutions earlier this year. As a result, Evergen became the industry’s only CDMO that offers a comprehensive portfolio of allograft and xenograft solutions.

Evergen said the new identity embodies its commitment to innovation, quality, and patient-centered regenerative medicine solutions. The company plans to set new industry benchmarks through customized solutions for cardiac, sports medicine, orthopedic surgery, neurosurgery, plastic and reconstructive surgery.

“This rebranding marks a defining moment in our Company’s evolution,” said Evergen president and CEO Olivier Visa. “Every decision we make begins with understanding patient needs and developing flexible, high-quality solutions that enable our customers to meet these needs effectively. As Evergen, we are positioned to lead a new era of regenerative medicine by becoming the trusted CDMO of choice for OEM partners.”

“Our new brand identity honors our rich heritage and unifies our employees as we become one team,” added Evergen’s chief people officer Kim Spooner. “As the newer businesses have integrated, it has been clear that there is a strong cultural affinity across our teams. I look forward to seeing how this further strengthens in the months and years ahead.”